Mounzer E Agha MD
Hematologic Oncology
Director, Mario Lemieux Center for Blood Cancers
Join to View Full Profile
5115 Centre Ave3rd FloorPittsburgh, PA 15232
Phone+1 412-864-6648
Fax+1 412-864-6666
Dr. Agha is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1992
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 1986 - 1989
University of Aleppo Faculty of MedicineClass of 1983
Certifications & Licensure
PA State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Clinical Trials
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.Kevin Quann, Konstantinos Lontos, Alison Sehgal, Anastasios Raptis, Annie Im
Haematologica. 2024-12-01 - Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows.Pranav Pramod Patwardhan, Joseph Franz, Mounzer Agha, Bryan Rea
American Journal of Clinical Pathology. 2024-07-20 - 6 citationsProspective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised Individuals.Ghady Haidar, Jacob C Hodges, Andrew Bilderback, Amy Lukanski, Kelsey Linstrum
The Journal of Infectious Diseases. 2024-05-15
Authored Content
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021
Press Mentions
Who Qualifies for a Coronavirus Booster Shot? Why It’s Still UnclearAugust 13th, 2021- Protecting the Immune-Compromised Keeps Everyone SafeAugust 5th, 2021
- The Complex Situation for Immunocompromised People and COVID-19 VaccinesJune 16th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
